Solutions for psychedelic-inspired drug development – backed by science
Psychedelics — full circle
We support the development of early and late-stage platforms to unleash the full potential of next generation pharmaceuticals inspired by psychedelics.
Our solutions are backed by over 10 years of experience in drug development including the chemistry, pharmacology, and safety evaluation of serotonergic drugs in vitro and in vivo.
We offer consulting services throughout the entire development pipeline to maximize the value and success rate of your assets as they move along.
You point the way, we take you there. We assist with implementation of different assay modalities, both in-house or through external contractors, execute evaluation, and interpret readouts to streamline decision-making throughout the drug development process and on to the next milestone.
Competitive intelligence for drug development in neuroscience
Identification of niche areas in the psychedelic and adjacent spaces
Management of synthesis of NCEs
Neuroplasticity models in vitro and in vivo
Head-twitch and models of 'psychedelicness'
Curated disease-relevant models
Gap analysis and risk mitigation in preclinical development
Safety monitoring and anticipation
GONOGO is led by Mario de la Fuente Revenga, PhD, PharmD. Over 10 years of experience in drug development and psychedelic science have cemented his conviction that psychedelics inspire what the drugs of tomorrow look like. Structurally, as chemical scaffolds, but also as a living example of new challenges and opportunities for drug development in neuroscience.